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INTRODUCTION:
Breast cancer is the most common malignancy in women worldwide, with more than 220,000 new cases reported in the United States alone in 2012, and is the second leading cause of female cancer-related death (1). The discovery of novel and effective chemopreventive agents for people at higher risk of developing mammary malignancies could help reduce cancer appearance or delay its progression. Among several agents under study, the biologically-active form and analogs of vitamin D appear promising due to their anti-proliferative, prodifferentiating, anti-inflammatory and immunomodulatory activities (2) .
Vitamin D (cholecalciferol) is the essential precursor to the potent steroid hormone calcitriol which has effects in almost every cell in the body and influences proliferation, differentiation and apoptosis events (3) (4) (5) (6) . Humans obtain vitamin D in their diet but the largest input occurs in the skin through sunlight conversion of 7-dihydrocholesterol to previtamin D 3 and cholecalciferol. Cholecalciferol is activated after hydroxylation into calcidiol (25(OH)D) by liver CYP27A1 hydroxylase, and further hydroxylation by renal CYP27B1 into the biologicallyactive calcitriol (1,25(OH) 2 D). Renal CYP27B1 is tightly regulated by calcium and parathyroid hormone to maintain optimal circulating levels of 1,25(OH) 2 D. Kidney was originally believed to be the only site of 1,25(OH) 2 D production . However, elevated 1,25(OH) 2 D levels observed after bilateral nephrectomy (7) suggested the existence of extra-renal hydroxylation, and CYP27B1 was subsequently confirmed in several tissues among which breast where tissuespecific signals control its activity, and its product 1,25(OH) 2 D is not secreted but mostly displays autocrine/paracrine effects (8) (9) (10) (11) (12) (13) (14) . To exert its biological activity, 1,25(OH) 2 discrete vitamin D-responsive elements in DNA as a ligand-activated transcription factor and influences the expression of hundreds of genes (6, 15) .
Despite a large body of evidence supporting an inverse association between vitamin D levels and cancer in general (5, 16) , and breast cancer in particular (17) (18) (19) (20) , the epidemiological evidence remains controversial (21) (22) (23) (24) and a 20,000 subject 5-year primary cancer and cardiovascular disease prevention trial for vitamin D (VITAL) is ongoing (25) . Since tissues do not respond to vitamin D identically, further studies are needed to determine the dose-response relation between vitamin D status and cancer risk, optimal treatment duration, time of life when exposure is most relevant, and optimal metabolite to use.
Various vitamin D metabolites present different absorption and transformation rates; cholecalciferol metabolism, for example, depends on hepatic health (26) and its circulating halflife is short (27) . Consequently, other natural and synthetic vitamin D metabolites are investigated for clinical use. Apart from its classical role in calcium and phosphate homeostasis, 1,25(OH) 2 D displays anti-neoplastic activity (28) , which proceeds through growth arrest and differentiation, induction of apoptosis, inhibition of invasion, metastasis and angiogenesis, as well as anti-inflammatory effects (29) . Most anti-cancer trials have been conducted with 1,25(OH) 2 D, however, a major drawback of this molecule is the possibility of toxic hypercalcemic side-effects (28) . An intermittent administration protocol must be followed to avoid hypercalcemia, and important benefits on tumor outcome is rarely seen (29) . Novel 1,25(OH) 2 D analogs with low calcemic capacity are widely used in treatment of psoriasis, secondary hyperparathyroidism and parathyroid hyperplasia (15) , but still cause hypercalcemia in cancer therapy where high doses must be used for long periods and produce inconsistent antitumor results (29 (16, 19, 30) . The presence of CYP27B1 in many target tissues including breast (31, 32) Metastases quantification: Female mice were sacrificed at 12 weeks. Exposed lungs were injected with 2 ml of 10% neutral buffered formalin by tracheal cannulation to fix inner air spaces and inflate the lung lobes, then excised and formalin-fixed 48 hours. Representative lungs were paraffin-embedded and processed for histological analysis. Care was taken so that any evident metastases dissected during sectioning were only represented once in the H and E stained slides. Lung metastases surfaces were scored in a genotype-blinded fashion with a Nikon SMZ- 
RESULTS:
Low vitamin D diet accelerates mammary hyperplasia and tumor growth in MMTV-PyMT mice.
Vitamin D nutritional input as a cancer-delaying approach was tested in female wild-type MMTV-PyMT mice by feeding the animals a normal (1000 IU/kg) or low (25 IU/kg) vitamin D 3 diet to achieve either normal or low circulating 25(OH)D levels, as described previously (41) . 
25(OH)D and 1,25(OH) 2 D perfusion significantly decreases lung metastasis:
In MMTV-PyMT mice, microscopic lung metastases spontaneously develop in animals by 12-13 weeks of age (43) . At sacrifice (12 weeks), lung sections from all mice revealed invasion (table 1) Continuous perfusion treatment with either vitamin D metabolite reduced expression of cell proliferation markers KI-67, ErbB2, and cell cycle progression marker cyclin D1 (Fig 3 A to   D) . MMTV-PyMT tumors are initially ER-α positive but eventually progress to ER-independent adenocarcinomas, while expression of cyclin D1 and HER2 persist (37, 44) . This confirms that 
DISCUSSION:
The vitamin D pathway has long been suspected of involvement in carcinogenesis prevention. Vitamin D deficiency is not only widespread in cancer patients, but correlates with advanced-stage disease independently of age, sex, and body mass index (47) . Vitamin Ddeficiency also enhances human breast cancer cell lines growth and metastasis in xenograft models (48) (49) (50) and increases the incidence of chemically-induced mammary lesions in rats (51).
However, the immune response is a crucial component of cancer progression, and carcinogen induction is a confounding factor, so we used here the MMTV-PyMT model of spontaneous oncogene-driven breast cancer which closely recapitulates the main features of aggressive human disease including distal metastasis (34, 36, 37) . While PyMT is not a human mammary oncogene, it activates c-Src/PI3K/Akt and Shc/ras/MAPK pathways like HER2 does (34, 44) . In 
